Cox J - Search Results

1

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.

Roach M 3RD, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J. Roach M 3RD, et al. Among authors: cox j. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):617-27. doi: 10.1016/s0360-3016(00)00577-0. Int J Radiat Oncol Biol Phys. 2000. PMID: 10837944

2

Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06.

Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J. Valicenti RK, et al. Among authors: cox j. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1323-9. doi: 10.1016/j.ijrobp.2010.01.009. Int J Radiat Oncol Biol Phys. 2011. PMID: 21414514 Clinical Trial.

3

Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.

Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, Lin X, Shipley WS. Roach M, et al. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1351-6. doi: 10.1016/j.ijrobp.2004.05.026. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590164 Clinical Trial.

4

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.

Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E. Movsas B, et al. Among authors: cox j. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1143-9. doi: 10.1016/s0360-3016(99)00325-9. Int J Radiat Oncol Biol Phys. 1999. PMID: 10613306 Clinical Trial.

5

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.

Chakravarti A, Heydon K, Wu CL, Hammond E, Pollack A, Roach M, Wolkov H, Okunieff P, Cox J, Fontanesi J, Abrams R, Pilepich M, Shipley W; Radiation Therapy Oncology Group. Chakravarti A, et al. Among authors: cox j. J Clin Oncol. 2003 Sep 1;21(17):3328-34. doi: 10.1200/JCO.2003.12.151. J Clin Oncol. 2003. PMID: 12947069

6

The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data.

Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J. Emami B, et al. Among authors: cox j. Lung Cancer. 2003 Aug;41(2):207-14. doi: 10.1016/s0169-5002(03)00228-9. Lung Cancer. 2003. PMID: 12871784

7

RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J. Valicenti RK, et al. Among authors: cox jd. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):614-20. doi: 10.1016/s0360-3016(03)00640-0. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529764 Clinical Trial.

8

Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.

Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. Michalski J, et al. Among authors: cox jd. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e363-70. doi: 10.1016/j.ijrobp.2011.12.070. Int J Radiat Oncol Biol Phys. 2012. PMID: 22633552 Free PMC article. Clinical Trial.

9

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M 3rd, Sandler HM, Pollack A, Cox JD. Ryu JK, et al. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1036-46. doi: 10.1016/s0360-3016(02)03006-7. Int J Radiat Oncol Biol Phys. 2002. PMID: 12419429 Clinical Trial.

10

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.

Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M 3rd, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW. Xiao C, et al. Among authors: cox jd. Adv Radiat Oncol. 2018 Jun 7;3(3):405-411. doi: 10.1016/j.adro.2018.04.010. eCollection 2018 Jul-Sep. Adv Radiat Oncol. 2018. PMID: 30202809 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,801 results

Search Page

Filters